The Annual Prescrire Awards

The Prescrire Drug Awards for 2023

	This year, none of the drugs we examined represented a major therapeutic advance worthy of a Pilule d'Or ("Golden Pill" Award). Only one drug made the Honours List.
The Pilule d'Or ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

• Blincyto° (blinatumomab) - Amgen
In high-risk first-relapse acute lymphoblastic leukaemia
in children

A notable reduction in mortality, demonstrated in two randomised comparative trials in children with high-risk first-relapse ALL, is a clear therapeutic advance that justifies blinatumomab's place on this year's Honours List.

Download the full article:

FREE "The Prescrire Awards for 2023" Prescrire Int 2024; 33 (259): 132-134. Free.

Back to "The Prescrire Awards for 2023"

Enjoy full access to Prescrire International, and support independent information

Subscribe now